Georgiamune is a company focused on reprogramming immune responses to fight cancer and autoimmune diseases by regulating signaling pathways to restore immune homeostasis.

Georgiamune

NextGen Life Sciences provides solutions in the fields of biotechnology and healthcare by offering testing equipment, reagents, kits, and instruments for medical research.

NextGen Life Sciences

Georgiamune Inc. is a private, science and discovery clinical stage immunotherapeutic biotechnology company focused on reprogramming immune signaling pathways to redirect the immune system to fight diseases. Unique approaches to re-establishing immune balance and groundbreaking scientific discoveries have led to the development of pioneering immune therapeutics for cancer and autoimmune diseases.

Parker Institute for Cancer Immunotherapy

Mubadala Capital Ventures

Verition Fund Management

General Catalyst

Bioventures Investors

Catalio Capital Management

Alexandria Venture Investments

Lauder Partners

Georgiamune Inc.

We’re incredibly proud our CEO and Founder Samir Khleif was named a winner of the prestigious EY Entrepreneur of the Year Awards for his pioneering work and groundbreaking innovations in novel biology discoveries. Congratulations to the other finalists and winners! 
 
To view all winners and learn more about the award, visit: https://go.ey.com/4eHrqW7 #EYEntrepreneurOfTheYear #EYAwards #EYEOY #novelbiology

Big news from our team today! We're excited to announce that GIM-531 has received IND clearance from the FDA. GIM-531 is a first-in-class oral treatment that selectively targets T-regulatory cells, while sparing other immune cells like CD4 and CD8. That's in addition to GIM-122, our first-in-class, dual-functioning antibody, which is in human clinical trials. 
 
We're proud to help propel novel science, and are another step closer to reprogramming immune signaling pathways to redirect the immune system to fight cancer and autoimmune diseases. Learn more: https://lnkd.in/gjtA5pRP 
#clinicaltrials #FDAclearance #cancer #firstinclass #noveldrugs

Founder and CEO Samir Khleif sat down with RJ Lumba on the Great Entrepreneurs Podcast. Hear Dr. Khleif shed light on his background, the origin of Georgiamune and our mission to reprogram immune signaling pathways to redirect the immune system to fight diseases. 

https://lnkd.in/gu7UMzsn 
#biotech #hiring

At Georgiamune Inc., we’re reprogramming immune signaling pathways to redirect the immune system to fight diseases. We’re excited to announce the clearance of our IND for our lead compound, GIM-122, a first-in-class, dual functioning monoclonal antibody. We’re also extremely grateful to the top-tier investors who helped us raise $75M in our Series A financing round. Learn more about our mission, our science and our team at www.georgiamune.com

#immunotherapy #immunooncology #biotech

Georgiamune is honored to be included on BioSpace’s prestigious List of the Top 30 Life Sciences Trailblazers for 2024! We are looking forward to 2024 as we continue to deliver novel drugs to restore immune homeostasis to fight cancer and autoimmune diseases. 

Learn more about our mission, our science, and our team at www.georgiamune.com.

#oncology #autoimmune #lifesciences #biotech

Our CEO Samir Khleif sat down with Rebecca Torrence from Business Insider to share progress on GIM-122's clinical trial, our first-in-class pipeline, and our $75 million in Series A funding, co-led by General Catalyst and Parker Institute for Cancer Immunotherapy.

Read the full article to learn how our novel biology is pioneering breakthroughs in cancer and autoimmune drugs: https://bit.ly/3vsRZMR #novelbiology #Georgiamune

Metric
Company Name	Georgiamune	NextGen Life Sciences
Symbol
MSH ID	COM:GEORGIAMUNE	COM:NEXTGENLIFE
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology
Country	US	IN
Stage
Employee Count	19
Website	georgiamune.com	nextgenlife.com
LinkedIn	georgiamune
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic		1.52K
Web Traffic Growth		1.11
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:GEORGIAMUNE

Georgiamune

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue